Dr MAK Lung Yi, Loey

Dr Loey Mak

Clinical Assistant Professor

  • MBBS(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine)
email lungyi@hku.hk
email 2255-6979
email ORCID
Biography
Dr Mak received her medical education at The University of Hong Kong. She obtained her qualification of the Membership of the Royal Colleges of Physicians of the United Kingdom in 2013 and the Postgraduate Diploma in Infectious Diseases by The Li Ka Shing Faculty of Medicine of The University of Hong Kong in 2015. She completed her specialty training in Gastroenterology and Hepatology in year 2018 and Advanced Internal Medicine in year 2019 at Queen Mary Hospital.

Dr Mak’s research interests include chronic hepatitis B, fibrosis assessment and treatment of chronic liver diseases, and biomarkers in gastrointestinal diseases. She has published more than 50 peer-reviewed articles in reputable journals. Highlights include invited editorials in Lancet Gastroenterology & Hepatology (impact factor 12.85), Alimentary Pharmacology & Therapeutics (impact factor 7.35) and the 'Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong' as first author, on behalf of The Hong Kong Society of Gastroenterology, The Hong Kong IBD Society, The Hong Kong Society of Digestive Endoscopy, and The Hong Kong Red Cross Blood Transfusion Service, which was published in The Hong Kong Medical Journal.

Dr Mak has received numerous academic awards, including the Dr Kate Cheng Memorial Prize for Postgraduate Diploma in Infectious Diseases, the Hong Kong Association for Study of Liver Disease Young Investigator Research Grant in 2015, the Best Abstract in Clinical Medicine in the Medical Research Conference organized by The University of Hong Kong in 2017, 2019 and 2020, the Young Investigators Award in the Asian Pacific Association of Gastroenterology 3rd Clinical Forum on Inflammatory Bowel Disease in 2018, and the travel award for the 7th Annual Meeting of Asian Organization of Crohn's & Colitis. She was also awarded the Faculty Knowledge Exchange Award by Li Ka Shing Faculty of Medicine, The University of Hong Kong in 2019.

Dr Mak received the Health and Medical Research Fund in year 2019 as a principal investigator for a 3-year project studying the regression of liver fibrosis in patients with chronic hepatitis B who achieved functional cure She is currently a council member for The Hong Kong Association for the Study of Liver Diseases (HKASLD). Dr Mak was part of the organising committee for the 24th Hong Kong Medical Forum. Dr Mak has delivered several invited lectures locally, and have chaired sessions in local scientific meetings. She gave numerous presentations for her research work in a number of overseas conferences. She has enrolled in the degree of Doctor of Medicine which will be completed by year 2021.

Selected publications
  1. Mak LY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. Lancet Gastroenterol Hepatol 2020 [in press]
  2. Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined use of common fecal and blood markers for detection of endoscopically active inflammatory bowel disease. Clin Transl Gastroenterol. 2020 [In press]
  3. Fung J, Mak LY, Chan AC, et al. Model for end-stage liver disease with additional criteria to predict short-term mortality in severe flares in chronic hepatitis B. Hepatology 2019 [In press]
  4. Mak LY, Lee CH, Cheung KS, et al. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int. 2019; 39(7):1217-1225.
  5. Mak LY, Seto WK, Hui RW, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019; 26(7):818-827.
  6. Mak LY. Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? Aliment Pharmacol Ther. 2019; 49(7):954-955.
  7. Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018; 38:262-279.
  8. Mak LY, Law CW, Hui YT, et al. Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong. Hong Kong Med J 2018; 24(4): 416-22.
  9. Mak LY, Wong DK, Cheung KS, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol. 2018;9(6):163.
  10. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther 2017.

Grant Record
  • Health and Medical Research Fund, HK Government Food & Health Bureau, 2018 (PI)
  • The Hong Kong Association for Study of Liver Disease Young Investigator Research Grant (2015)

Key Office
  • Council Member, The Hong Kong Association for Study of Liver Disease